文献速递头颈部肿瘤放疗

日本国民健康保险体系下硼中子俘获治疗复发头颈部鳞状细胞癌的临床结果与预后因素:首批47例患者的回顾性研究

Clinical Results and Prognostic Factors in Boron Neutron Capture Therapy for Recurrent Squamous Cell Carcinoma of the Head and Neck Under the Japan National Health Insurance System: A Retrospective Study of the Initial 47 Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-04-03

该回顾性研究分析了2020年5月至2021年2月在日本接受硼中子俘获治疗(BNCT)的47例复发头颈部鳞状细胞癌患者的早期临床结果与预后因素。结果显示完全缓解率为51%,总缓解率为74%,1年和2年总生存率分别为86.1%和66.5%。多因素分析显示病变是否位于黏膜对达到完全缓解有显著影响。

要点

  • BNCT治疗后完全缓解率为51%,总缓解率为74%。
  • 1年和2年总生存率分别为86.1%和66.5%,无病生存率分别为34.6%和26.6%。
  • 多因素分析显示病变位于黏膜对达到完全缓解有显著影响。

核心结论

  • 该研究为BNCT融入常规临床实践提供了有价值的早期见解,强调了其疗效和安全性。
  • 需要技术改进以确保精确的剂量给予。
  • 正在进行的前瞻性研究(如II期REBIVAL研究)将进一步阐明BNCT在复发头颈部癌中的作用。

研究设计与样本

  • 回顾性分析纳入2020年5月至2021年2月在日本接受BNCT治疗的首批47例复发头颈部鳞状细胞癌患者。
  • 所有患者此前均接受过放疗,中位剂量为70 Gy(范围44-176 Gy)。
  • 中位肿瘤大小为11 cm3(范围1-117 cm3),23%的肿瘤大于30 cm3,87%的患者接受过既往全身治疗。
  • 咽黏膜最常见处方剂量为15 Gy-Eq(36%),其次为18 Gy-Eq(34%);肿瘤最低剂量为27.4 Gy-Eq(范围13.3-45.2 Gy-Eq)。
  • 23例患者在BNCT前1周内接受了18F-氟硼苯丙氨酸正电子发射断层扫描,肿瘤与血液的10B比值为3.5(范围2.0-8.7)。

主要发现

  • 疗效分析显示完全缓解率为51%,总缓解率为74%。
  • 1年和2年无病生存率分别为34.6%和26.6%。
  • 1年和2年总生存率分别为86.1%和66.5%。
  • 多因素分析显示,在患者特征中,病变是否位于黏膜对达到完全缓解有显著影响。

关键数值与推荐

  • 完全缓解率为51%,总缓解率为74%。
  • 1年和2年无病生存率分别为34.6%和26.6%。
  • 1年和2年总生存率分别为86.1%和66.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recurrent head and neck cancer presents a therapeutic challenge because of cumulative toxicity from initial radiation therapy, limiting reirradiation options. Boron neutron capture therapy (BNCT) offers a promising alternative, selectively delivering a radical dose to tumors while sparing adjacent normal tissue. This study investigates the initial clinical outcomes and prognostic factors associated with BNCT for recurrent squamous cell carcinoma of the head and neck. METHODS AND MATERIALS: This retrospective analysis investigated the initial 47 patients treated with BNCT between May 2020 and February 2021 in Japan. All patients had received radiation therapy with a median dose of 70 Gy (range, 44-176) before BNCT. Median tumor size was 11 cm3 (range, 1-117 cm3), with 23% of tumors larger than 30 cm3, and 87% of patients had prior systemic therapy. The most common prescribed dose to the pharyngeal mucosa was 15 Gy-Eq (36%), followed by 18 Gy-Eq (34%). The minimum dose given to tumor was 27.4 Gy-Eq (range, 13.3-45.2). In 23 patients, 18F-fluoro-borono-phenylalanine positron emission tomography was performed within 1 week before BNCT, and the tumor-to-blood 10B ratio was 3.5 (range, 2.0-8.7). RESULTS: Efficacy analysis revealed a 51% complete response rate and a 74% overall response rate. Disease-free survival rates at 1 and 2 years were 34.6% and 26.6%, respectively. Overall survival rates at 1 and 2 years were 86.1% and 66.5%, respectively. Multivariate analysis revealed that, among the patient characteristics, whether the lesion was mucosal had a significant effect on achieving complete response. CONCLUSIONS: This study provided valuable insights into the early integration of BNCT into routine clinical practice, highlighting its efficacy and safety. Technical improvements are needed to ensure precise dose administration. Ongoing prospective studies, such as the phase II REBIVAL study, will further elucidate the role of BNCT in recurrent head and neck cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hirose K, Sato M. Clinical Results and Prognostic Factors in Boron Neutron Capture Therapy for Recurrent Squamous Cell Carcinoma of the Head and Neck Under the Japan National Health Insurance System: A Retrospective Study of the Initial 47 Patients. Int J Radiat Oncol Biol Phys. 2024. PMID: 38580084. doi:10.1016/j.ijrobp.2024.03.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。